Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy
Source
bskySemaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophydoi.orgYou might also wanna read
Clinical Trial Finds Ozempic Reverses Biological Age by 3.1 Years
The diabetes drug Ozempic has shown significant anti-aging effects in a clinical trial, reversing biological age by an average of 3.1 years
trial.medpath.com·11mo ago
Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse mo
GLP-1 drugs show early promise for treating substance use disorders, but evidence remains preliminary
GLP-1 receptor agonists (like semaglutide and tirzepatide), already transformative for obesity and diabetes, are being investigated as a pot
mdsc.pe·2d ago
AAV-mediated FGF21 gene therapy extends health span and lifespan in aged mice through multi-tissue adaptations
This study demonstrates that a one-time muscle-directed AAV-mediated FGF21 gene therapy in aged and geriatric mice extends health span and l
Study Finds Ozempic Does Not Slow Alzheimer's Disease Progression
Novo Nordisk announced that its popular weight-loss drug Ozempic does not slow the progression of Alzheimer's disease, based on results from
semafor.com·7mo ago
ADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlighted
An interview with Dr. Rita Kalyani, the ADA's chief scientific and medical officer, discussing key research presented at the ADA 2026 Scient
ja.ma·15d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.